Opko Health Inc (OPK) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Opko Health Inc $0.24, price $1.56, upside -84.6%, quality 32 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Opko Health Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $0.8655 – $5.15 · fair‑value band $0.1800 – $0.3500 · the $1.56 price screens above the $0.2400 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Opko Health in your weekly email
Every Wednesday you see whether Opko Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics.
Show more
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.
Stock analysis
Opko Health Inc (OPK) currently trades at $1.56, while our model-based Fair Value estimate is $0.2400, 84.6% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $0.1800 (bear) to $0.3500 (bull), the price of $1.56 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Opko Health Inc reported revenue of $607M in FY2025 versus $1.8B in FY2021, a compound −23.5%/yr. Reported net income was −$226M in FY2025.
Key figures
Market cap $1.2B · P/S ratio 1.85 · EPS (TTM) $−0.2700 · Net margin −37.2% · Return on equity −16.9% · Return on assets (EBIT) −7.1% · Operating margin −41.1% · Revenue (TTM) $581M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 10% below its 52-week high and 42% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −85%, OPK screens richer than that median.
Fair Value models
Bear $0.1800Fair Value $0.2400Bull $0.3500
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−14.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.8%
Start year 2020 (pandemic). Over 10 years: +2.1% a year
Revenue growth 30 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
4.0% (2020) → −36.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 135 stocks
Beats the industry median on 2/10 measures
Overall it trails its industry peers.
Valuation
Quality Score32 · Bottom 25%
Fair Value upside−84.7% · Bottom 25%
Profitability
Return on assets−6.4% · Bottom 25%
Net margin (TTM)−36.6% · Bottom 25%
Operating margin (TTM)−41.1% · Bottom 25%
Growth and dividend
Revenue growth−17.2% · Bottom 25%
Balance sheet
Debt / equity0.26× · Above median
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/B0.93× · Cheaper than median
P/S (TTM)2.03× · Cheaper than median
PEG93.65× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 28
PAST (return on equity)0· sector 10
HEALTH (low debt)87· sector 93
DIVIDEND (yield)0· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Opko Health Inc Fair Value". https://www.fairvalue-calculator.com/stock/OPK
Frequently asked questions
Is Opko Health Inc (OPK) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.2400 versus a price of $1.56, about −85% upside (overvalued).
What is the fair value of OPK?
Our model-based fair value for Opko Health Inc is $0.2400 (as of Sep 24, 2026), built from audited fundamentals. The current price: $1.56.
What is the quality score of OPK?
Opko Health Inc has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Opko Health Inc (OPK)?
Our model-based price target is the fair value of $0.2400 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $0.1800, optimistic scenario $0.3500. It is a calculation from audited fundamentals, not an analyst target.
What is the Opko Health Inc stock forecast for 2026?
Our models put fair value at $0.2400, about −85% upside versus a price of $1.56 (overvalued). Cautious scenario $0.1800, optimistic scenario $0.3500. The calculation is refreshed regularly with new filings.
What is the revenue of Opko Health Inc (OPK)?
Opko Health Inc reported trailing-twelve-month revenue of about $581M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Opko Health Inc (OPK)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Opko Health Inc it is $0.2400 per share (as of Sep 24, 2026), against a price of $1.56. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Opko Health Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, OPK trades above its calculated fair value: price $1.56, fair value $0.2400, a gap of about −85% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OPK?
No. The price is what the market pays today ($1.56); the fair value is what the company's own numbers justify ($0.2400). For Opko Health Inc the two are $1.32 per share apart. That gap is exactly why we show both numbers side by side.
How much is Opko Health Inc worth?
The market values Opko Health Inc at about $1.2B (market capitalisation, as of Sep 24, 2026). Per share that is $1.56; our models calculate a fair value of $0.2400 per share.
What do the bullish and bearish scenarios say about OPK?
Our models span a range for Opko Health Inc: cautious scenario $0.1800, base $0.2400, optimistic $0.3500 per share (as of Sep 24, 2026, price $1.56). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of OPK?
The PEG ratio of Opko Health Inc is 93.65 (P/E divided by earnings growth, as of Sep 24, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Opko Health Inc (OPK)?
Balance-sheet figures for Opko Health Inc (as of Sep 24, 2026): return on equity −16.9%, debt of 0.26 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is OPK from its 52-week high?
Opko Health Inc trades at $1.56, about 10% below its 52-week high of $1.73 and 42% above the low of $1.10 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.2400 is for.
Which stocks are comparable to Opko Health Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Opko Health Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $1.56, calculated fair value $0.2400 (−85%), Quality Score 32/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of OPK calculated?
We run Opko Health Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.2400, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Opko Health Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Opko Health Inc (OPK)?
The closing price on Oct 2, 2026 was $1.56. Our model-based fair value is $0.2400, about −85% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Opko Health Inc right now?
The price sits above even our optimistic bull case ($0.3500). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.1800 to $0.3500) leaves room in how you read the outcome.
Key figures of Opko Health Inc
How large is the market capitalisation of Opko Health Inc (OPK)?
The market capitalisation of Opko Health Inc is $1.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Opko Health Inc (OPK)?
The price-to-sales ratio of Opko Health Inc is 1.85 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Opko Health Inc (OPK)?
Earnings per share at Opko Health Inc are $−0.2700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Opko Health Inc (OPK)?
The net margin of Opko Health Inc is −37.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Opko Health Inc (OPK)?
The return on equity (ROE) of Opko Health Inc is −16.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Opko Health Inc (OPK)?
On an EBIT basis the return on assets of Opko Health Inc is −7.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Opko Health Inc (OPK)?
The operating margin of Opko Health Inc is −41.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Opko Health Inc (OPK)?
Revenue at Opko Health Inc is growing −17.2% versus a year earlier (3y avg −15.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Opko Health Inc (OPK)?
Earnings per share at Opko Health Inc are growing −12.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Opko Health Inc (OPK) generate?
The free cash flow of Opko Health Inc is −$191M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Opko Health Inc (OPK) carry?
The net debt of Opko Health Inc is $64.5M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Opko Health Inc in the live analysis
One click puts Opko Health Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 24, 2026